Abstract: Methods and compositions are disclosed for protecting an organ or tissue from inflammation and organ injury following ischemia, reperfusion, and trauma through the administration of an HMGB1 protein within a time period sufficient to protect the organ or tissue from injury.

Abstract: The present invention relates to methods and compositions of treating patients suffering from, or at risk for, hemorrhagic shock. The treatment includes administering to the patient a pharmaceutical composition that includes carbon monoxide.

Abstract: The present invention relates to the construction of a TRAIL DNA cassette for the production of a secretable trimeric rTRAIL, the development of pCMVdw vectors and pAAVdw vectors harboring a feed-forward amplification loop type Tet-On system that can be packaged into AAV particles, the preparation of a recombinant vectors by the combination of the TRAIL DNA cassette and the two vectors, and the treatment of diseases including cancer using such vectors.

Abstract: The invention provides a pharmaceutical composition comprising as an active ingredient a pharmaceutical agent comprising a DNA sequence that codes for a protein which possesses the biological activity of inducible nitrogen monoxide synthase (iNOS) and eukaryotic regulation elements, wherein the eukaryotic regulation elements result in the expression of said DNA sequence in eukaryotic cells, and a pharmaceutically acceptable carrier. The pharmaceutical agent can be complexed to liposomes.

Abstract: The present invention provides a method of promoting the closure of a wound in a patient. This method involves transferring exogenous iNOS to the region of the wound whereby a product of iNOS is produced in the region of the wound to promote the closure of the wound. The present invention also provides a method of transplanting a graft into a patient, which method involves transferring a vector comprising an iNOS expression cassette to cells associated with the graft and surgically incorporating the graft tissue into the patient. Upon expression of iNOS within the patient, a product of iNOS is produced in the region of the graft to attenuate vasculopathy in the region of the graft.

Abstract: A human tissue inducible nitric oxide synthase cDNA clone is disclosed. A process for preparing this cDNA clone coding for human tissue inducible nitric oxide synthase and for expressing the human tissue inducible nitric oxide synthase protein are provided.

Abstract: The present invention provides a method of promoting the closure of a wound in a patient. This method involves transferring exogenous iNOS to the region of the wound whereby a product of iNOS is produced in the region of the wound to promote the closure of the wound.

Abstract: A method for the treatment of mammalian tissue injured or at risk of injury during sepsis or shock including the administration to a mammal a diazeniumdiolate which releases a therapeutically effective amount of nitric oxide sufficient to protect the tissue from sepsis- or shock-induced injury.

Abstract: The present invention discloses a full-length human hepatocyte iNOS cDNA clone and various gene therapy applications utilizing an iNOS DNA sequence. In preferred embodiments of the disclosed invention, iNOS-directed gene therapy involves specific targeting of a DNA sequence encoding a protein or protein fragment with iNOS biological activity for treating vascular diseases and disorders, antitumor applications and in response to certain microbial infections.

Abstract: A human tissue inducible nitric oxide synthase cDNA clone is disclosed. A process for preparing this cDNA clone coding for human tissue inducible nitric oxide synthase and for expressing the human tissue inducible nitric oxide synthase protein are provided.